Further development is required to speed commercialisation
- Pre-clinical studies for influenza to refine the dose levels and vaccination schedules
- Phase 1/2 clinical trials for influenza
- Parallel development for TB
- Exploration of other uses for the technology
To enable this, we are seeking an investment of £20 million. We anticipate results within 18 months.